RespireRx Pharmaceuticals Inc (RSPI)

[atheroprevent]

Nice post DD.

"Neuroscience has largely been a burial ground for drug development" (quote from British biopharma perspective)

The academia-biotech partnership development model still fails ....lack of financing given development cost, regulatory burden and capital risk.

Today's Corx trade interest pays for 5 days of Alzheimer care. Who will frontload any milestones or cover R+D costs? That's why we are at 7 for $1.

As implied in the parallel antibiotic story, with decades of failed investment (and drying up of antibiotic R+D), we now have patients helplessly dying with multiantibiotic resistant strains of bacteria.